BioCardia, Inc. BCDA 深 滬
已收盤 06-05 16:00:00 美东时间
1.03
+0.111
+12.08%
華盛通- 最 高1.80
- 今 開1.195
- 成交量 1.51亿股
- 最 低 1.02
- 昨 收 0.919
- 總市值 1171.60万
- 52周最高 2.45
- 市盈率 靜 --
- 換手率 1328.48%
- 52周最低 0.8404
- 委 比 -70.21%
- 總股本 1137.47万
- 歷史最高 129.00
- 量 比 1530.20
- 振 幅 84.87%
- 歷史最低 0.8404
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is BioCardia Stock Gaining Friday?
BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 resistance? Get the technical outlook.
06-05 23:06
BioCardia Receives FDA Confirmation For Its Biologics Evaluation And Research On CardiAMP Cell Therapy System To Treat Ischemic Heart Failure Of Reduced Ejection Fraction
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its Q-Sub Meeting
06-05 20:03
BioCardia Announces Presentation Of Data From CardiAMP Minimally-Invasive Chronic Myocardial Ischemia Treatment Trial Demonstrating Positive Clinical Outcomes
Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimally invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major adverse cardiac events
05-21 20:04
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
BioCardia's CardiAMP Cell Therapy trial shows positive results for patients with severe refractory angina, demonstrating improved exercise tolerance and reduced angina episodes. The minimally invasive procedure was well-tolerated with no major adverse events. Patients experienced a 179-second increase in exercise capacity and an 82% reduction in angina episodes within six months. This novel cell therapy addresses an unmet need for patients who ha...
05-21 12:00
电话会总结 ｜ BioCardia(BCDA)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BioCardia业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩：- **净亏损**：2026年第一季度净亏损230万美元，较2025年同期的270万美元减少40万美元 - **总费用**：2026年第一季度总费用230万美元，较上一季度减少46万美元 - **运营现金流**：2026年第一季度运营活动净现金使用170万美元，略高于2025年同期的160万美元 - **现金及现金等价物**：季度末余额为95.1万美元 ## 2. 财务指标变化：- **研发费用**：同比下降29.5万美元至120万美元（2025年第一季度为150万美元
05-19 12:17
BioCardia Q1 2026 Earnings Call: Complete Transcript
BioCardia (NASDAQ:BCDA) released first-quarter financial results and hosted an ...
05-16 04:54
BioCardia Q1 EPS $(0.21) Misses $(0.17) Estimate
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 64.41 percent increase over losses of $(0.59) per share from the
05-15 20:20
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
BioCardia Says FDA Raised No Safety Concerns, Outlines Two Clearance Pathways For Helix Catheter System
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the outcome of its Pre-Submission Meeting
05-08 20:04
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
BioCardia announced FDA agreement on two pathways for Helix Transendocardial Delivery Catheter marketing clearance, with no concerns raised on safety or performance. FDA preferred simultaneous approval with CardiAMP cell therapy for heart failure. CEO Peter Altman expressed gratitude and aim to pursue both pathways to enhance development and partnerships. Helix enables precise delivery of agents to the heart, while CardiAMP uses bone marrow cells...
05-08 12:00
